Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Accounts Payables (2020 - 2025)

HCW Biologics (HCWB) has disclosed Accounts Payables for 6 consecutive years, with $116000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables fell 90.33% year-over-year to $116000.0, compared with a TTM value of $116000.0 through Sep 2025, down 90.33%, and an annual FY2024 reading of $981940.0, down 84.08% over the prior year.
  • Accounts Payables was $116000.0 for Q3 2025 at HCW Biologics, down from $19.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $19.4 million in Q2 2025 and bottomed at $116000.0 in Q3 2025.
  • Average Accounts Payables over 5 years is $3.7 million, with a median of $1.7 million recorded in 2021.
  • The sharpest move saw Accounts Payables soared 697.53% in 2024, then tumbled 90.33% in 2025.
  • Year by year, Accounts Payables stood at $2.1 million in 2021, then dropped by 17.52% to $1.7 million in 2022, then surged by 256.42% to $6.2 million in 2023, then plummeted by 84.08% to $981940.0 in 2024, then plummeted by 88.19% to $116000.0 in 2025.
  • Business Quant data shows Accounts Payables for HCWB at $116000.0 in Q3 2025, $19.4 million in Q2 2025, and $1.2 million in Q1 2025.